6533b7d3fe1ef96bd12606d2

RESEARCH PRODUCT

Action immunitaire de chimiothérapies anticancéreuses : un exemple à travers les modes d'actions des cellules "Interferon-producting Killer Dendritic Cells".

subject

description

Classical antitumoral therapies are basically perceived as a direct and lytic action of the chosen therapeutic agent against tumor cells. Nevertheless, growing evidence indicates that some anticancer strategies can work through the action of the immune system. Imatinib Mesylate (IM), a targeted drug, helped us to unravel some mechanisms of action of a natural killer sub-population: the "Interferon-producing Killer dendritic Cells" (IKDC). Thoses cells possess anti-tumoral lytic capacities, synergistically amplified by IM and interleukine (IL)-2, under the dependency of IL-15, and also antigen-presenting capability. Those cells are capable of TRAIL-mediated lysis and of antigen uptake, processing and presentation to naives T cells.